Table 6Acute Coronary Syndrome Among Patients in the Randomized Controlled Trials

RCTTreatment Duration (No. Randomized)STEMI %Non-STEMI %Unstable Angina %
PRODIGY6 mo (983)
24 mo (987)		33.3
32.5		22.5
22.9		18.5
18.5
DES-LATE12 mo (2,514)
24 mo (2,531)		12.5
12.4		10.6
10.6		38.6
36.7
ARCTIC-Interruption12 mo (641)
18-30 mo (645)		NRNRNR
ITALIC6 mo (926)
24 mo (924)		0.1
0.3		7.3
7.1		15.7
16.4
DAPT12 mo (4,941)
30 mo (5,020)		10.3
10.6		15.5
15.5		16.7
16.7
OPTIDUAL12 mo (697)
48 mo (701)		11.9
10.7		17.0
14.2		9.1
9.5
Hu 201212 mo (NR)a
36 mo (NR)		NRNRNR

mo = months; NR = not reported; STEMI = ST-segment elevation myocardial infarction.

a

216 patients total.

From: Results

Cover of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Review of the Clinical Impact of Treatment Duration
Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Review of the Clinical Impact of Treatment Duration [Internet].
CADTH Technology Review, No. 8.
Wells GA, Elliott J, Kelly S, et al.
Copyright © 2017 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.